LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Applied DNA’s COVID-19 Diagnostic Kit Granted FDA EUA Amendment for Use on Widely Installed RT-PCR Device and High-Throughput RNA Extraction Robotics

By LabMedica International staff writers
Posted on 03 Aug 2020
Print article
Illustration
Illustration
Applied DNA Sciences Inc. (Stony Brook, NY, USA) has been granted Emergency Use Authorization (EUA) amendment by the US Food and Drug Administration (FDA) that expands the installed base of PCR equipment platforms which can process the company’s Linea COVID-19 Assay Kit and introduces automation to significantly increase the throughput of the assay by use of robotic RNA extraction.

The EUA amendment extends the RT-PCR platform authorization from the Applied Biosystems (ThermoFisher Scientific) QuantStudio Dx to include Applied Biosystems’ QuantStudio 5 Real-Time PCR system (QS5). The amendment also authorizes the use of the Hamilton STARlet robotic automation in conjunction with the Omega Bio-tek Mag-Bind viral RNA Express kit to speed the process of extracting viral RNA from specimens and drive greater testing throughput. The company believes the amendment can greatly enhance the efficiency of laboratories across the US who adopt the diagnostic kit while expanding by more than tenfold the target installed base of authorized RT-PCR equipment. To match the potential for higher demand, the company is increasing production of its diagnostic kit.

“Accessibility and turnaround times are two critical metrics for the successful commercial implementation of a diagnostic kit to serve communities affected by the COVID-19 crisis. With this EUA amendment we have accomplished both – a greatly increased installed base of RT-PCR devices upon which our assay can run, and also increased the speed and throughput of our assay through the use of a best-in-breed robotic platform. We appreciate the continued collaboration of FDA in assisting us to improve the availability and throughput of our diagnostic kit,” said Dr. James A. Hayward, president and CEO of Applied DNA. “As COVID-19 infection numbers spike in many parts of the country, we are also moving to increase kit production. We have been investing aggressively in our supply chains and established inventories to deliver greater patient accessibility to testing and for maximal market penetration.”

“Our mission at Hamilton each day is to supply advanced liquid handling solutions that support the research and diagnostic testing communities confronting the COVID-19 pandemic,” said Michael Mouradian, vice president of Robotics at Hamilton Company, manufacturer of the Hamilton STARlet platform.

“We appreciate the opportunity to work with Applied DNA Sciences to help provide a reliable, reproducible RNA extraction solution,” said Travis Butts, vice president of Omega Bio-tek, manufacturer of the Omega Bio-tek Mag-Bind viral RNA Express kit. “By partnering with Hamilton, we are able to implement an automated, high-throughput solution that can be deployed quickly and allow customers like Applied DNA Sciences to meet the demand for COVID-19 testing.”

Related Links:
Applied DNA Sciences Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more